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Abstract
Two structurally different forms of activated human Factor IX
(Factor IXaa and IXa8) have been previously reported to have
essentially identical clotting activity in vitro. Although it has
been shown that activated Factor IXChapel Hills an abnormal
Factor IX isolated from the plasma of a patient with mild
hemophilia B, and normal Factor IXaa are structurally very
similar, the clotting activity of activated Factor IXC,,,pe Hill iS
much lower (approximately fivefold) than that of normal Factor
IXaj. In the present study we have prepared activated Factor
IX by incubating human Factor IX with calcium and Russell's
viper venom covalently bound to agarose. Fractionation of the
activated Factor IX by high-performance liquid chromatography
demonstrated the presence of both Factors IXaa and IXMaf.
On the basis of active site concentration, determined by
titration with antithrombin III, the clotting activities of activated
Factor IXO-ap.1 Hill and IXaa were similar, but both activities
were <20% of the clotting activity of Factor IXaf. Activated
Factor IX activity was also measured in the absence of calcium,
phospholipid, and Factor VIII, by determination of the rate of
Factor X activation in the presence of polylysine. In the
presence of polylysine, the rates of Factor X activation by
activated Factor IXChpe Hills Factor IXaa, and Factor IXa$
were essentially identical. We conclude that the clotting activity
of activated Factor IXCh-.p. Hill is reduced when compared with
that of Factor IXaft but essentially normal when compared
with that of Factor IXaa.
Introduction
Hemophilia B is a sex-linked hereditary bleeding disorder
related to a plasma deficiency in functional blood coagulation
Factor IX (1, 2). Plasma deficiencies in functional Factor IX
result when there is a defect in the expression of the Factor
IX gene or when the product of gene expression is structurally
abnormal. Hemophilia B has been subclassified according to
the plasma level of Factor IX antigen or cross-reacting material
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(CRM)' to antisera specific for Factor IX (3). In previous
studies we investigated the structure/function of abnormal
Factor IX isolated from the plasma of CRM' hemophilia B
patients, i.e., patients with essentially normal plasma Factor
IX antigen levels but significantly decreased Factor IX clotting
activity (3). Factor IXChapel Hill, isolated from the plasma of a
CRM' hemophilia B patient with a clinically mild bleeding
tendency, has been studied in some detail (4-6). Factor
IXChapel Hill is activated by incubation with Factor XIa/calcium,
but the rate of activation is somewhat slower than the rate of
activation of normal Factor IX (5). In addition, the apparent
clotting activity of activated Factor IXChapel Hill is only 20% of
the clotting activity of activated normal Factor IX.2 Activation
of Factor IXChapel Hill was associated with the cleavage of only
one (Argl 80-Val 181) of the two sites cleaved by Factor XIa/
calcium during the activation of normal Factor IX (Argl45-
Ala146, Argl80-Vall81) (5). Recently we reported that the
structural defect in Factor IXChhapel Hill is in the substitution of
histidine for arginine at position 145 in the primary structure
(6), which would appear to explain the inability of Factor XIa/
calcium to cleave the protein at this site.
The cleavage/activation of bovine and human Factor IX
by a protease present in Russell's viper venom (RW-X) has
been reported (7, 8). Cleavage of Factor IX by RVV-X/calcium
occurs predominantly at one site (human Factor IX, Arg180-
Vall8 1; bovine Factor IX, Arg18 1-Val 182) to produce Factor
IXaa (M, = 57,000). Factor IXaa is composed of two poly-
peptide chains, which are held together by disulfide bonds.
The specific clotting activity of bovine Factor IXaa has been
reported to be -twofold lower than the clotting activity of
bovine Factor IXafi (7). Factor IXafi is also composed of two
polypeptide chains held together by disulfide bonds, but the
additional cleavage of the protein at a second site (human
Factor IX, Argl45-Alal46; bovine Factor IX, Arg146-Alal47)
appears to release an activation peptide (Mr = 11,000), with a
1. Abbreviations used in this paper: CRM, cross-reacting material;
HPLC, high-performance liquid chromatography; kA;. apparent first
order rate constant for Factor X activation by activated Factor IX;
PEG, polyethylene glycol; RVV, Russel's viper venom; RVV-X, a
protease present in Russell's viper venom; TEA, triethanolamine;
TosGlyProArgNaN, Na-p-tosyl-glycyl-L-prolyl-L-arginine-p-nitroanilide.
2. The term activated factor IX is used when the specific structure,
i.e., bond cleavage sites, is not indicated. The terms Factor XIa/
calcium and RVV/calcium indicate that Factor IX was activated by
incubation with Factor XIa or RVV in the presence of calcium. The
term Factor X/polylysine activity refers to Factor X activation by
activated Factor IX in the presence of polylysine. The term clotting
activity refers to the procoagulant activity of activated Factor IX in
Factor IX deficient plasma.
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concomitant decrease in the apparent molecular weight of the
protein to -45,000 (7-9). The specific clotting activities of
human Factors IXaa and IXa have been reported to be
essentially identical (8). This observation, however, is incon-
sistent with the finding that the specific clotting activity of
activated Factor IXc,,d Hill, which is structurally very similar
to Factor IXaa, is only 20% of the clotting activity of Factor
IXa,6 (5).
Factor IXaa is cleaved to Factor IXaft during prolonged
incubation with RVV-X/calcium (8). This observation suggests
that a given preparation of Factor IXaa would contain Factor
IXafl, which could increase the apparent clotting activity of
the preparation. The present investigation was therefore un-
dertaken to determine rigorously the relative clotting activities
of activated Factor lyCh~pe Hill, Factor IXaa, and Factor IXafB.
Factor IXaa, prepared by incubation with Russell's viper
venom (RVV)/calcium, was separated from Factor IXaI3 by
high-performance liquid chromatography (HPLC) before mea-
surement of clotting activity. We have also measured the rates
of Factor X activation by these enzymes in the presence of
polylysine (10). This system was found to be very useful in
measuring activated Factor IX concentrations by titration with
antithrombin III and offered an approach for evaluating en-
zymatic activities in the absence of cofactors (calcium, phos-
pholipid, Factor VIII) that are present in the clotting activity
assay. We have found that the Factor X/polylysine activities
of these enzymes are essentially identical, whereas the clotting
activities of activated Factor IXapd Hill and Factor IXaa are
only 20% of the clotting activity of Factor IXaf.
Methods
Materials. Polylysine, M, = 65,000 and RVV were purchased from
Sigma Chemical Co. (St. Louis, MO). Na-p-Tosyl-glycyl-L-prolyl-L-
arginine-p-nitroanilide (TosGlyProArgNaN) was purchased from Boeh-
ringer Mannheim Biochemicals (Indianapolis, IN). Bovine brain cephalin
(Thrombofax) was purchased from Ortho Pharmaceutical (Raritan,
NJ). Polyethylene glycol (PEG; M, = 6,000) and triethanolamine (TEA)
were purchased from Fisher Scientific Co. (Raleigh, NC).
Proteins. Factors IX and X were isolated from human plasma by
a procedure incorporating various aspects of published procedures (I 1,
12). In brief, Factors IX and X were adsorbed from plasma with
barium citrate. The proteins were eluted from the barium citrate with
40% ammonium sulfate. The ammonium sulfate eluate was dialyzed
against 0.02 M sodium phosphate (pH 5.9), 0.1 M NaCl, 1.0 mM
benzamidine and applied to a 2.5 X 30 cm DEAE-cellulose (DE-52;
Whatman Chemical Separation, Inc., Clifton, NJ) column equilibrated
with the dialysis buffer. Factors IX and X were eluted from the column
with a I liter gradient from 0.1 to 0.55 M NaCI.
Factors IX and X (as well as prothrombin), which coelute from
the DEAE-cellulose column, were separated from one another by
dextran sulfate-agarose column chromatography as previously described
(12). Effluent fractions from the dextran sulfate-agarose column con-
taining Factors IX and X were separately pooled and concentrated by
adsorption to and elution from a 1.0-cc bed volume DEAE-cellulose
column. The preparations of Factor IX (200 U/mg) and Factor X
(100 U/mg) were homogeneous as judged by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (13). Prothrombin was not
detected in the Factor IX or X preparations as measured by the
generation of thrombin after prolonged incubation of samples with
Echnis carinatus venom. Protein concentrations were determined
spectrophotometrically at 280 nm by the use of extinction coefficient
values of 1.33 and 1.16 ml mg-' cm-' for Factors IX and X,
respectively (11). Factor IXC,.pd Hill was isolated from hemophilia B
patient plasma by the procedure described above for the isolation of
normal Factor IX. Factor IX and X preparations were dialyzed
overnight at 4VC against 0.05 M Tris HC1 (pH 7.4), 0.15 M NaCG.
The dialyzed preparations were incubated for 30 min at room tem-
perature with 10 mM diisopropylphosphofluoridate before storage
at -700C.
Human antithrombin III was isolated from barium citrate-adsorbed
plasma by heparin-agarose affinity chromatography essentially as de-
scribed previously (14). The preparation was judged to be homogeneous
by SDS-polyacrylamide gel electrophoresis (13). Antithrombin III
concentration was determined spectrophotometrically at 280 nm by
means of an extinction coefficient value of 0.6 ml mg-' cm-' (14).
When an M, of 65,000 was used (14), 1 mol of purified antithrombin
III was required to inactivate I mol of human a-thrombin in the
presence or absence of heparin (15).
Human Factor XIa was partially purified from Celite (Celite 545;
Johns-Manville Sales Corp., Denver, CO) activated human plasma as
described previously (5). Factor XIa and RVV3 were covalently coupled
to agarose (Sepharose 4B) by the procedure described previously (16).
Measurement of activated Factor IX by plasma clotting activity.
The clotting activities of solutions containing activated Factor IX were
determined by the addition of 0.075-ml sample to a fibrometer cup
containing 0.075 ml of nonactivated Factor IX deficient plasma and
0.075 ml Thrombofax. After the mixture was warmed to 370C, 0.075
ml of 25 mM calcium chloride was added and the fibrometer was
started. The clotting times of normal Factor IXa# solutions, ranging
in concentration from 2.5 to 250 nM (0.01125 to 11.25 Mg/ml), were
used to construct a standard curve. The clotting time of a given
activated Factor-IX solution was converted to the equivalent normal
Factor IXaj# concentration from the standard curve. Therefore, activated
Factor IX concentrations, determined by clotting activity, are expressed
in micrograms or moles of normal Factor IXaj6 per unit volume.
Measurement ofactivated Factor IX by Factor X/polylysine activity.
Activated Factor IX was added to a solution containing 400 nM Factor
X, 50 nM polylysine, 0.3 mM TosGlyProArgNaN, 0.1 M TEA (pH
8.0), 0.1 M NaCl, and 0.1% PEG. After the solution was mixed it was
transferred to a 1.0-cm path length cuvette, which was then placed in
a Beckman Acta CIII spectrophotometer (Beckman Instruments, Inc.,
Palo Alto, CA). The change in absorbance at 400 nm was measured
as a function of incubation time at room temperature. The rate of
change in absorbance per minute of incubation time (dcddt) increased
linearly with incubation time (t) as described by the following first
order rate equation:
dA4w/dt = kid C- t, (1)
where k," is the apparent first order rate constant for Factor X
activation by activated Factor IX, and C is the rate of change in A.4w
due to the hydrolysis of TosGlyProArgNaN by Factor Xa Under the
experimental conditions described above, the value of C was 1.374
X 10' (ODU/min)/M Factor Xa. This value was determined by the
addition of a known amount of Factor Xa (RVV-agarose/calcium
activated Factor X, active site titrated by the use of antithrombin III)
to the buffer/polylysine/TosGlyProArgNaN solution and measurement
of the initial rate of increase in A.4o.
The absorbance (Am4m) at any given incubation time was described
by the integrated form of Eq. 1.
Al = A,-C.t2/2 + C-t + AZO (2)
In Eq. 2, C' is the rate of change in A.4w due to the hydrolysis of
TosGlyProArgNaN by Factor Xa (or other enzymes) present in the
3. Russell's viper venom, as obtained commercially, was- used in the
present study without fractionation to obtain the specific protease
(RVV-X) responsible for Factor IX activation. The results of preliminary
work with the unfractionated-venom and purified RVV-X were not
measurably different in terms of the relative rates of cleavage of the
Argl80-Vall8 1 and Argl45-Ala146 bonds.
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reaction solution at zero time. Since the value of C' was variable (see
Results), for each series of assays a control was run in which buffer
was added to the reaction solution instead of activated Factor IX. The
absorbance of the control at incubation time t (A4w), was therefore
equal to C'- t + AZ3, where AZ° is the absorbance of the reaction
solution at zero time. It is important to note that the addition of
activated Factor IX to the reaction solution, in the absence of Factor
X, did not have a measurable effect on the absorbance of the solution
over the incubation times used in the present study. By substitution
of A~w into Eq. 2 and rearrangement of the equation, the value of kb,
could be determined at any incubation time according to the following
equation:
kdX = (A" - Aoo)2/C- t2. (3)
For routine assay purposes, the final activated Factor IX concentration
was varied up to a final concentration of -50 nM in a total reaction
volume of 0.5 ml. The incubation time was varied according to the
concentration range of activated Factor IX in a given assay series.
TosGlyProArgNaN hydrolysis was terminated by the addition of 0.5
ml of 50% acetic acid, and the absorbance was measured.
The absorbance values of the control and test solutions were
substituted into Eq. 2 along with the incubation time for the assay
series, and kow was calculated. The value of C was corrected for the
dilution of the reaction solution due to the addition of acetic acid.
Under these conditions, A4w values of <0.35 were proportional to the
amount of Factor Xa formed during the incubation time. The ko;M
values were proportional to the activated Factor IX concentration up
to at least 50 nM and corresponded to a rate of Factor X activation
of 0.035 mol Factor Xa/min per mol of activated Factor IX.
Measurement of activated Factor IX concentration by active site
titration with antithrombin III. Activated Factor IX was added to a
series of solutions containing from 50 to 250 nM antithrombin III,
0.01 mg/ml heparin, 0.1 M TEA (pH 8.0), 0.1 M NaCl, and 0.1%
PEG. The final activated Factor IX concentration (assuming complete
activation of a known concentration of Factor IX) was -250 nM.
The solutions were incubated at room temperature for 20 min after
the addition of activated Factor IX. Samples (0.02 ml) were then
removed and added to a solution (0.5 ml) containing 400 nM Factor
X, 50 nM polylysine, 0.3 mM TosGlyProArgNaN, 0.1 M TEA (pH
8.0), 0.1 M NaCl, and 0.1% PEG. After incubation for 10 min at
room temperature, 0.5 ml of 50% acetic acid was added. The absorbance
at 400 nm of each solution was measured and the rate of Factor X
activation (kt.) was calculated according to Eq. 3. The rate of Factor
X activation was plotted as a function of the antithrombin III
concentration and the x-intercept value, corresponding to the concen-
tration of antithrombin III required to neutralize completely the
activated Factor IX, was determined by linear regression analysis of
the data. Under the assumption that 1 mol of antithrombin III is
required to neutralize 1 mol of activated Factor IX, the activated
Factor IX concentration corresponded to the x-intercept value. The y
intercept values, corresponding to the rate of Factor X activation by
the diluted activated Factor IX solution in the absence of antithrombin
III, was then used to calculate the rate of Factor X activation per mol
of activated Factor IX.
Preparation of activated Factor IX. Factor IX was added to a
solution containing 0.05 M Tris HC1 (pH 7.4), 0.15 M NaCl, 7.0 mM
CaCI2, 0.1% PEG, and either Factor XIa-agarose or RVV-agarose. The
final Factor IX concentration was -400 nM (0.225 mg/ml). The
amount of Factor XIa-agarose or RVV-agarose was adjusted such that
Factor IX activation, as determined by Factor X/polylysine activity,
was completed within 4 to 6 h of incubation at room temperature.
Complete conversion of Factor IX to its activated forms was confirmed
by SDS-polyacrylamide gel electrophoresis after sample reduction with
,B-mercaptoethanol. Incubation of normal Factor IX with Factor XIa-
agarose/calcium resulted in conversion of the protein to the Factor
IXafl structure, whereas Factor IX0,hp HiD was converted to the Factor
IXaa structure. Incubation of normal Factor IX with RVV-agarose/
calcium resulted in conversion of the protein to the Factor IXaa
structure predominantly, with a time dependent conversion (30%O in
6 h) to the Factor IXa,8 structure (see Results). Prolonged incubation
of normal Factor IX with RVV-agarose/calcium (-24 h) resulted in
nearly quantitative conversion of the Factor IXaa to Factor IXap.
Incubation of Factor IXChpd Hill with RVV-agarose/calcium resulted in
conversion of the protein to the Factor IXaa structure only. The
concentration of activated Factor IX in a given solution was determined
by active site titration with antithrombin III.
Size exclusion chromatography ofactivated Factor IX. Factor IXap8
could be separated from Factor IXaa and unactivated Factor IX by
HPLC with Spherogel-TSK 3000 SW column (7.5 mm X 30 cm; Altex
Scientific, Inc., Berkeley, CA). The running buffer was 0.05 M Tris/
HCl (pH 7.0), 0.5 M NaCl, and the flow rate was 0.5 ml/min. In a
typical experiment, 0.2-ml sample containing 0.225 mg/ml of protein
was injected and a 5.5-ml fraction was collected before the collection
of 0. 12-ml fractions. Essentially 100% of the protein, as determined
by activity assays, was recovered in all experiments. The separation of
Factor IXafi from Factor IXaa (and Factor IX) was somewhat better
than expected strictly on the basis of the molecular weight differences.
The elution volume of Factor IXaa (7.3 ml) corresponded to an
apparent molecular weight of 80,000 (actual molecular weight, 57,000),
whereas the elution volume of Factor IXapi (8.3 ml) corresponded to
an apparent molecular weight of 45,000, which is the actual molecular
weight of Factor IXaft.
Results
Factor X activation by activated Factor IX in the presence of
polylysine. Factor IXapi, prepared by incubation of normal
Factor IX with Factor XIa-agarose/calcium, was added to a
solution containing Factor X, polylysine, and TosGlyPro-
ArgNaN, and the absorbance of the solution at 400 nm was
followed spectrophotometrically over a 10-min incubation
time. A similar experiment was run in which buffer was added
instead of Factor IXafl. In the presence of Factor IXafl, the
absorbance increased nonlinearly with incubation time, whereas
in the absence of Factor IXap, the absorbance increased
linearly. These results are shown in Fig. 1. The rate of change
in absorbance (AA4A) per minute of incubation time in the
presence of Factor IXaM was plotted as a function of incubation
time. As shown in the inset in Fig. 1, the AA400 per minute
values increased linearly with incubation time which, according
to Eq. 1, indicated that the activation of Factor X by Factor
IXa,# in the presence of polylysine followed first order kinetics
over the 10-min incubation. From the slope of the line (Fig.
1, inset), kob was calculated according to Eq. 1 to be equal to
0.30 nM Factor Xa/min. The absorbance values at t = 10 min
for both experiments (A400 = 0.365, A~w = 0.135) were used
in Eq. 3 to calculate the kob; 0.30 nM Factor Xa/min. It is
apparent that either method of calculation gives equivalent
values for kb,.
The linear increase in absorbance observed in the absence
of Factor IXa(# suggested that trace amounts of Factor Xa
were present in the Factor X preparation. For the experiment
shown in Fig. 1, the rate of increase in absorbance was 0.0135
ODU/min, which corresponds to a Factor Xa concentration
of - 1.0 nM. Since the Factor X concentration in the experi-
ment was 400 nM, only 0.25% of the preparation appeared to
be activated. The amount of Factor Xa present in the Factor
X prepartion was variable, however, and appeared to increase
with storage at 4°C. Since the Factor X preparation, treated
with diisopropylfluorophosphate immediately after isolation,
was initially devoid of amidolytic activity, it appeared that a
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Figure 1. Synthetic substrate hydrolysis vs. Factor IXaO/Factor X
incubation time in the presence of polylysine. Factor IXaO was added
to a solution containing 400 nM Factor X, 50 nM polylysine, 0.3
mM TosGlyProArgNaN, 0.1 M TEA (pH 8.0), 0.1 M NaCI, 0.1%
PEG, and the absorbance at 400 nm (A4w) was monitored spectro-
photometrically (-). The final factor IXa,6 concentration was 8.65
nM. The experiment was repeated in the absence of Factor IXa, (m).
(Inset) The AA4/min values obtained in the presence of activated
Factor IX were calculated over I-min time increments and are
plotted against the incubation time.
protease able to activate Factor X in the absence of calcium
was a contaminant of the preparation. The protease is not
susceptible to inhibition by diisopropylfluorophosphate or able
to hydrolyze TosGlyProArgNaN. Storage of the Factor X
preparation at -70°C greatly decreased Factor X activation;
therefore, freshly thawed Factor X solutions were used in all
subsequent experiments. A control, however, was run for each
assay series.
The rates of activation of Factor X in the presence of
polylysine by Factor IXaj and activated factor IXh, Hill were
not measurably different. Solutions containing approximately
equal concentrations of both enzymes were titrated with
antithrombin III to determine the active site concentrations.
As shown in Fig. 2, the residual Factor X/polylysine activities
of the solutions decreased linearly with increasing antithrombin
III concentration. On the basis of the amount of antithrombin
III that was required to inhibit completely the Factor X/
polylysine activity of the enzyme solution, the initial concen-
trations of Factor IXaft and activated Factor IXChw,,, Hill were
225 and 295 nM, respectively. For both enzymes, the rate of
Factor X activation was 0.035 mol Factor Xa/min per mol of
active sites.
Factor IX activation by R VV-agarose/calcium. Incubation
ofnormal Factor IX with RW-agarose/calcium was associated
with an increase in Factor X/polylysine and clotting activities.
A significant difference between the apparent activated Factor
IX concentrations as determined by the two activity assays
was observed, however. These results are shown in Fig. 3. The
activated Factor IX concentration, measured by Factor X/
polylysine activity (0.225 mg/ml), appeared to indicate complete
activation of Factor IX after >4 h of incubation. The activated
Factor IX concentration, measured by clotting activity, in-
creased continually over the 6-h incubation. Since the activated
Factor IX concentration, determined by both activity assays,
is based on the activity of Factor IXaft (i.e., Factor IXafl was
used to construct the standard curves used to determine the
activated Factor IX concentration), the results suggest that the
predominant form of activated Factor IX obtained by incu-
bation of Factor IX with RW-agarose/calcium, i.e., Factor
IXaa, has significantly lower clotting activity than does Factor
IXafi. The factor X/polylysine activities of Factors IXaa and
IX appear to be essentially equivalent. Under the assumption
that the Factor X/polylysine activity measured concentration,
the clotting activity of Factor IXaa is <20% of the clotting
activity of Factor IXa#t.
Samples taken at timed intervals from the Factor IX/RW-
agarose/calcium incubation mixture were fractionated by
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Figure 2. Determination of the activated Factor IX concentration by
titration with antithrombin III. Antithrombin III was added to a
solution containing approximately equal amounts of either Factor
IXa, (e) or activated Factor IXciape Hill (A), 0.01 mg/ml heparin, 0.1
M TEA (pH 8.0), 0.1 M NaCl, 0.1% PEG, and incubated for 20 min
at room temperature. Samples (0.02 ml) were removed and added to
a solution (0.5 ml) containing 400 nM Factor X, 50 nM polylysine,
0.3 mM TosGlyProArgNaN, 0.1 M TEA (pH 8.0), 0.1 M NaCI, 0.1%
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Figure 3. Factor IX activation by RVV-agarose/calcium. RVV-aga-
rose was added to a solution containing normal Factor IX (0.225
mg/ml), 0.05 M Tris HCI (pH 7.4), 0.15 M NaCl, 0.1% PEG, 7.0
mM CaC12, and incubated at room temperature. At timed intervals
samples were removed and assayed for activated Factor IX by Factor
X/polylysine activity (-) and clotting activity (-) as described in
Methods. The amount of activated Factor IX was determined from
standard curves, which related either Factor X/polylysine activity or
clotting activity to normal Factor IXa concentration.














vated normal Factor IX.
Factor IX was incubated
with RVV-agarose/calcium
as described in the legend
to Fig. 3. At timed inter-
vals, 0.2-ml samples were
removed and chromato-
graphed by HPLC as de-
scribed in Methods. After a
5.5-ml fraction was col-
lected (not shown), 0. 12-ml
fractions were collected and
assayed for activated Factor
IX by Factor X/polylysine
activity (-) and by clotting
activity (-) as described in
Methods.
all of the Factor X/polylysine activity was present in a single
peak. By 4 h, however, a second peak of Factor X/polylysine
activity could be distinguished, which, by 6 h of incubation,
was quite pronounced. The ratio of clotting activity to Factor
X/polylysine activity in the first peak was 0.17, whereas the
ratio in the second peak was essentially 1.0. These results
indicate that the increase in clotting activity observed with
prolonged incubation of Factor IX with RVV-agarose/calcium
(Fig. 3) is associated with the conversion of Factor IXaa to a
lower apparent molecular weight form of Factor IX, which is
as active as Factor IXa,3 in the clotting and Factor X/
polylysine activity assays.
The second peak of Factor X/polylysine activity obtained
with RVV-agarose/calcium activated Factor IX (Fig. 4) eluted
from the HPLC column in the same volume as the Factor X/
polylysine activity in Factor XIa-agarose/calcium activated
Factor IX, i.e., Factor IXafl. These results are shown in Fig.
5. Samples of RVV-agarose/calcium activated Factor IX were
subjected to SDS-polyacrylamide gel electrophoresis under
nonreducing conditions. Most of the RVV-agarose/calcium
activated Factor IX migrated at the same rate as unactivated
Factor IX, and a small amount of the protein migrated at the
same rate as Factor IXa# (not shown). A sample of activated
Factor IX obtained after prolonged incubation with RVV-
IXa.t IXaji Figure 5. High-performance
size exclusion chromatogra-
. \ ,rE phy of activated Factor IX.
Normal Factor IX (0.145
mg/ml) was incubated with
either RVV-agarose (-) or
*'ir. .. \. Factor XIa-agarose (-) in a
o,I- + solution containing 0.05 M
10 12 14 16 18 20 22 24 26 28 30 Tris HCI (pH 7.4), 0.15 M
FRACTION NUMBER NaCl, 0.1% PEG, 7.0 mM
CaCI2. After -2 h, the amount of activated Factor IX, as deter-
mined by Factor X/polylysine activity, in both incubation mixtures
was 0.145±0.01 mg/ml. Samples (0.1 ml) were then chromato-
graphed and assayed for activated Factor IX activity as described in
the legend to Fig. 4.
agarose/calcium was analyzed for amino terminal amino acid
sequences. On three successive sequencer cycles, the following
amino acids were identified: (a) Tyr, Val, Ala; (b) Asn, Val,
Glu; and (c) Ser, Gly, Thr. These results are consistent with
the cleavage of Factor IX at the Argl45-Alal46 and Argl8O-
Val 181 bonds, which would generate the light chain (Tyr-Asn-
Ser), heavy chain (Val-Val-Gly), and activation peptide (Ala-
Glu-Thr) sequences observed with Factor IXal# (8).
The concentrations of various activated Factor IX solutions
were determined by both Factor X/polylysine activity and
clotting activity. The ratio between the concentrations deter-
mined by clotting activity and Factor X/polylysine activity
was defined as the relative activity of the activated Factor IX
preparation. The relative activity of Factor IXaft was 1.0
according to this definition. The relative activities of Factor
IXaa (0.17) and activated Factor IXChp.1 Hill (0.19) were
essentially identical. These results are summarized in Table I.
Discussion
Activated Factor IXChapel Hill and Factor IXaa are structurally
very similar. Both enzymes are formed by cleavage of a single
peptide bond (Argl80-Vall8 1), which produces molecules
consisting of two polypeptide chains held together by disulfide
bond(s) (5, 8). The carboxyl-terminal polypeptide chain (235
residues) of activated Factor IXChwl1 Hill and Factor IXaa
corresponds to the heavy chain of Factor IXa(l and contains
the active site residues of the enzymes. The amino-terminal
polypeptide chains (180 residues) consist of the y-carboxyglu-
tamic acid residue-containing light chain of Factor IXafl plus
the activation peptide which is produced when Factor IXap& is
formed. The primary structural difference between activated
Factor IX0p Hill and Factor IXaa appears to be the substitution
of histidine for arginine at position 145 (6).
In an earlier report we suggested that the enzymatic
properties of activated Factor IXChapel Hill and Factor IXaa
should be similar (6). In the present study we have shown that
the clotting activities of activated Factor IX1C.1 Hill and Factor
IXaa are very similar but <20% of the clotting activity of
Factor IXafl. We conclude from this observation that the
clotting activity of activated Factor IX-Clme Hill is abnormal, as
compared with that of Factor IXafl. This further suggests that
the substitution of histidine for arginine at position 145 in the
primary structure of Factor IXChpel Hill, while severely limiting
cleavage at this site by Factor XIa/calcium, does not have a
Table I. Concentrations ofActivated Factor IX Determined
by Factor X/Polylysine and Clotting Activities
Factor X/polylysine Clotting Relative
Factor IXa activity activity activity
[Factor IXaflJ 2.25 jAM 2.25 jIM 1.0
[Factor IXaaJ 2.79 MM 0.48 MM 0.17
[Factor IXacHJ 2.95 jIM 0.56 MM 0.19
Activated Factor IX solutions were assayed for Factor X/polylysine
and clotting activities and the activities were converted to the corre-
sponding concentrations from standard curves as described in Meth-
ods. The concentration of activated Factor IX determined by clotting
activity was divided by the concentration determined by Factor X/
polylysine activity to obtain the relative activity value. Factor IXCH,
Factor IXYQhp Hill-






























measurable effect on the clotting activity relative to Fac-
tor IXaa.
Activation of human Factor IX by incubation with RVV-
agarose/calcium has been shown to be associated with the
rapid cleavage of the Argl80-Vall81 peptide bond, but addi-
tional cleavage has been observed (8). In the present study we
have shown that two enzyme forms ofFactor IXa are produced
by RVV-agarose/calcium cleavage of Factor IX. The predom-
inant enzyme produced was Factor IXaa whereas the second
enzyme was indistinguishable from Factor IXaMO, as suggested
previously (8). In our initial attempts to prepare Factor IXaa
we used much larger amounts of RVV-agarose than in the
present report. Although this greatly decreased the incubation
time required to activate the Factor IX, we found that the
clotting activity rapidly approached the clotting activity expected
for Factor IXaf, as reported by DiScipio and co-workers (8).
In view of the results obtained in the present study it appears
that the formation of Factor IXafi could account for the
apparently similar clotting activities of Factors IXaa and IXao8
when Factor IX is activated by larger amounts of RVV-
agarose.
The clinical bleeding tendency of the patient with hemo-
philia B Chapel Hill is very mild. Only under conditions where
there is a major challenge to the hemostatic process, e.g.
surgery, does the patient appear to have significant bleeding.
Since Factor IX1apd Hill is activated to an essentially normal
Factor IXaa molecule, several interesting possibilities about
the role of Factor IX in normal hemostasis can be considered.
For example, it has been shown that <2% of the Factor IX
present in normal plasma is activated when plasma clots in
vitro (17). If Factor IX activation is not the rate limiting step
during hemostasis, then enough Factor IXcMa, Hill may be
activated for relatively normal hemostasis to occur. Alterna-
tively, the recent work of Link and Castellino has shown that
the differences between the enzymatic properties of bovine
Factors IXaa and IXaM can be related to differences in the
interactions of these enzymes with cofactors (18). Normal
hemostasis probably presents activated Factor IX with cofactor
concentrations which are considerably different from those
encountered in an in vitro clotting activity assay. Therefore,
the enzymatic properties of activated Factor IXha1pel Hill may
be essentially equal to those of Factor IXa,8 under the conditions
encountered during normal challenge to the hemostatic process.
Under the conditions encountered during major challenge to
the hemostatic process, however, the defect in Factor IXChael
Hill results in a significant bleeding diathesis.
The present study has shown that activated Factor
IXChapel Hill, Factor IXaa, and Factor IXafi activate Factor X
at similar rates in the presence of polylysine. This observation
is interesting in that it indicates that there are conditions under
which the three enzymes are essentially equally active. The
mechanism of action of polylysine in accelerating the rate of
Factor X activation by activated Factor IX is not known,
however, and it is difficult to compare rates of Factor X
activation in the presence of polylysine with rates of activation
observed in the presence of cofactors (calcium, phospholipid,
Factor VIlla). In an earlier study we observed a rate of Factor
X activation of 20.5 mol Factor Xa/min per mol Factor IXa#
in the presence of 5 U/ml Factor VI1a and optimal levels of
calcium and phospholipid (19). This rate is obviously much
greater ('600-fold) than the rate of Factor X activation in the
presence of polylysine observed in the present study. Although
this suggests that polylysine is not as effective as calcium,
phospholipid, Factor VIIIa in promoting Factor X activation,
the conditions for Factor X activation in the presence of
polylysine used in the present study may not have been
optimal. In any event, the similar rates of Factor X activation
in the presence of polylysine by the three enzymes studied
herein suggests that the enzymes are structurally/functionally
similar with respect to interactions with Factor X and polylysine,
whereas cofactor interactions, as measured by relative clotting
activities, appear to differ significantly. Furthermore, these
results appear to indicate that the active site regions of the
three enzymes are similar with respect to the Factor X binding
domain and the active sites residues required for the cleavage
of Factor X. Determination of the mechanism of action of
polylysine may reveal structural properties of activated Factor
IX that are important for cofactor (calcium, phospholipid,
Factor VIIIa) interactions and a better understanding of the
structure/function of Factor IX.
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